Department of Gynecology and Obstetrics, Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Institute of Gynecological Minimally Invasive Surgery Research Center, Tongji University School of Medicine, Shanghai 200072, China.
Department of Gynaecology and Obstetrics, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Biomed Pharmacother. 2019 Dec;120:109449. doi: 10.1016/j.biopha.2019.109449. Epub 2019 Oct 15.
Ovarian cancer is one of the most common gynecologic cancers with high morbidity and mortality in women. Glycogen metabolism plays a critical role in cancer development and glycogen phosphorylase B (PYGB) has reported to be involved in various tumors. Here, we explored the role of PYGB in ovarian cancer.
PYGB mRNA expression were examined in ovarian cancer tissue and also analyzed using the dataset from The Cancer Genome Atlas cohort. Correlations between PYGB expression and prognosis of ovarian cancer patients were analyzed. PYGB was silenced to evaluate the ovarian cell proliferation, invasion and migration in vitro and tumorigenesis in vivo. MiR-133a-3p targeting PYGB was identified using online tools and confirmed with luciferase reporter experiment. MiR-133a-3p overexpression using miRNA mimics was conducted to evaluate its function on ovarian cancer cells.
We showed that PYGB was upregulated in ovarian cancer tissue and high level of PYGB expression is markedly correlated with poor prognosis of ovarian cancer patients. PYGB knockdown significantly suppressed ovarian cancer cell proliferation, invasion and migration. Xenograft tumor formation further demonstrated that knockdown PYGB inhibited ovarian tumor development. Bioinformatics analysis revealed that PYGB regulated Wnt/β-catenin signaling pathway in ovarian cancer cells. Mechanistically, miR-133a-3p directly bound to 3'-untranslated region of PYGB and overexpression miR-133a-3p suppressed proliferation, invasion and migration in ovarian cancer cells.
Our data suggest that miR-133a-3p/PYGB/Wnt-β-catenin axis plays a critical role in human ovarian cancer, which might serve as a promising therapeutic target of ovarian cancer treatment in the future.
卵巢癌是妇科常见的恶性肿瘤之一,在女性中发病率和死亡率较高。糖代谢在癌症的发生发展中起着关键作用,糖原磷酸化酶 B(PYGB)已被报道参与多种肿瘤。本研究探讨了 PYGB 在卵巢癌中的作用。
检测卵巢癌组织中 PYGB 的 mRNA 表达,并使用癌症基因组图谱队列的数据集进行分析。分析 PYGB 表达与卵巢癌患者预后的相关性。沉默 PYGB 以评估其对卵巢癌细胞体外增殖、侵袭和迁移以及体内肿瘤形成的影响。使用在线工具鉴定 miR-133a-3p 靶向 PYGB 的靶点,并通过荧光素酶报告实验进行验证。使用 miRNA 模拟物过表达 miR-133a-3p,评估其对卵巢癌细胞的功能。
我们发现 PYGB 在卵巢癌组织中上调,高水平的 PYGB 表达与卵巢癌患者的不良预后显著相关。PYGB 敲低显著抑制卵巢癌细胞的增殖、侵袭和迁移。异种移植肿瘤形成进一步表明,敲低 PYGB 抑制了卵巢肿瘤的发展。生物信息学分析显示,PYGB 调节卵巢癌细胞中的 Wnt/β-catenin 信号通路。机制上,miR-133a-3p 直接结合 PYGB 的 3'-非翻译区,过表达 miR-133a-3p 抑制卵巢癌细胞的增殖、侵袭和迁移。
我们的数据表明,miR-133a-3p/PYGB/Wnt-β-catenin 轴在人卵巢癌中起关键作用,可能成为未来卵巢癌治疗的有前途的治疗靶点。